-
Publication Venue For
-
SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia..
69:e29760.
2022
-
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group..
69:e29644.
2022
-
Recommended scoring approach for the pediatric patient-reported outcomes version of the Common Terminology Criteria for Adverse Events..
69:e29452.
2022
-
SARS-CoV-2 vaccine acceptability among caregivers of childhood cancer survivors..
69:e29443.
2022
-
Pediatric cancer outcomes after the implementation of a residential hostel in Tanzania..
e29758.
2022
-
Factors contributing to delayed childhood cancer care in low- and middle-income countries: A systematic review protocol..
69:e29646.
2022
-
Extent of hypertension and renal injury in children surviving acute lymphoblastic leukemia..
e29628.
2022
-
Perceptions of specialty palliative care and its role in pediatric stem cell transplant: A multidisciplinary qualitative study..
69:e29424.
2022
-
Broaching goals-of-care conversations in advancing pediatric cancer..
68:e29270.
2021
-
Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains..
68:e29257.
2021
-
Parental limited English proficiency in pediatric stem cell transplantation: Clinical impact and health care utilization..
68:e29174.
2021
-
Pyruvate kinase deficiency in children..
68:e29148.
2021
-
Esophageal disease among childhood cancer survivors-A report from the Childhood Cancer Survivors Study..
68:e29043.
2021
-
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma..
68:e29084.
2021
-
Histologic maturation of cerebral neuroblastoma following conventional chemotherapy..
68:e29034.
2021
-
Integration of cancer registry and electronic health record data to construct a childhood cancer survivorship cohort, facilitate risk stratification for late effects, and assess appropriate follow-up care..
68:e29014.
2021
-
Hepatic vascular malignancies in children are associated with increased rates of surgical resection and improved overall survival compared with adults..
68:e28864.
2021
-
Response criteria for intraocular retinoblastoma: RB-RECIST..
68:e28964.
2021
-
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042)..
68:e28879.
2021
-
General cancer screening practices among adult survivors of retinoblastoma: Results from the Retinoblastoma Survivor Study..
68:e28873.
2021
-
Impacts of COVID-19 on caregivers of childhood cancer survivors..
68:e28943.
2021
-
Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe..
68:e28938.
2021
-
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe..
68:e28798.
2021
-
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction..
68:e28574.
2021
-
How I approach hereditary hemolytic anemia and splenectomy..
67:e28337.
2020
-
Osteomyelitis in sickle cell disease: You know it when you see it?.
67:e28585.
2020
-
Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study..
67:e28425.
2020
-
Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation..
67:e28370.
2020
-
Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update..
67:e28389.
2020
-
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia..
67:e28112.
2020
-
Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment..
67:e28160.
2020
-
Correlates of successful transition in young adults with sickle cell disease..
66:e27939.
2019
-
Insights into pediatric rhabdomyosarcoma research: Challenges and goals..
66:e27869.
2019
-
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study..
66:e27736.
2019
-
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer..
66:e27568.
2019
-
Ethical considerations of using a single minor donor for three bone marrow harvests for three HLA-matched siblings with primary immunodeficiency..
66:e27602.
2019
-
Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma..
66:e27491.
2019
-
Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity..
66:e27463.
2019
-
Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study..
65:e27304.
2018
-
Translation, psychometric validation, and baseline results of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health-related quality of life of patients with pediatric lymphoma in Malawi..
65:e27353.
2018
-
Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life..
65:e27081.
2018
-
Bleeding and thrombotic complications of pediatric liver transplant..
65:e26955.
2018
-
Inconsistency in classifying vascular anomalies: What's in a name?.
65.
2018
-
Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumor..
65.
2018
-
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group..
64.
2017
-
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience..
64.
2017
-
Renal medullary carcinoma: A national analysis of 159 patients..
64.
2017
-
The clinical severity of hemoglobin S/Black (A γδβ)0 -thalassemia..
64.
2017
-
A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group..
64.
2017
-
Development of quality indicators for transition from pediatric to adult care in sickle cell disease: A modified Delphi survey of adult providers..
64.
2017
-
Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents..
64.
2017
-
Reply to comment on: Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease..
64.
2017
-
Hepatocellular adenoma among adult survivors of childhood and young adult cancer..
64.
2017
-
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program..
64.
2017
-
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program..
64.
2017
-
Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative..
64.
2017
-
Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease..
63:2123-2130.
2016
-
Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia..
63:1856-1859.
2016
-
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program..
63:1744-1752.
2016
-
Understanding splenectomy for children with hereditary spherocytosis..
63:1700-1701.
2016
-
Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease..
63:1031-1037.
2016
-
Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery..
63:1038-1045.
2016
-
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program..
63:443-450.
2016
-
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program..
63:276-286.
2016
-
Tobacco Use Among Siblings of Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study..
63:326-333.
2016
-
Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience..
62:2216-2222.
2015
-
Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations..
62:1855-1858.
2015
-
Use of patient registries and administrative datasets for the study of pediatric cancer..
62:1495-1500.
2015
-
Value of surgical resection in children with high-risk neuroblastoma..
62:1529-1535.
2015
-
Cerebrospinal fluid proteomics in children during induction for acute lymphoblastic leukemia: A pilot study..
62:1190-1194.
2015
-
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program..
62:1106-1109.
2015
-
Is low dose hydroxyurea the solution to the global epidemic of sickle cell disease?.
62:929-930.
2015
-
Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children?.
62:922-923.
2015
-
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673..
62:91-98.
2015
-
Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program..
61:1972-1979.
2014
-
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program..
61:1486-1489.
2014
-
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program..
61:1493-1496.
2014
-
Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial..
61:1427-1433.
2014
-
Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study..
61:1440-1444.
2014
-
Patterns of symptoms and functional impairments in children with cancer..
61:1282-1288.
2014
-
Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome..
61:1126-1128.
2014
-
Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers..
61:1074-1079.
2014
-
Respiratory syncytial virus and seasonal influenza cause similar illnesses in children with sickle cell disease..
61:875-878.
2014
-
Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group..
61:729-736.
2014
-
Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program..
61:245-252.
2014
-
Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies..
61:360-362.
2014
-
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program..
61:158-164.
2014
-
Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children..
60:1967-1974.
2013
-
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program..
60:1860-1867.
2013
-
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program..
60:1325-1332.
2013
-
Reduced cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia..
60:1358-1364.
2013
-
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program..
60:E42-E45.
2013
-
The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians..
60:1231-1236.
2013
-
Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program..
60:783-790.
2013
-
Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program..
60:791-798.
2013
-
A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group..
60:543-549.
2013
-
High rates of recurrent biliary tract obstruction in children with sickle cell disease..
60:650-652.
2013
-
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program..
60:633-641.
2013
-
Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience..
60:694-699.
2013
-
Potential role for statins in sickle cell disease..
60:550-557.
2013
-
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program..
59:1266-1274.
2012
-
Ambulatory care connections of Medicaid-insured children with sickle cell disease..
59:888-894.
2012
-
Severe fetal and neonatal hemolytic anemia due to a 198 kb deletion removing the complete β-globin gene cluster..
59:941-944.
2012
-
Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program..
59:749-752.
2012
-
Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program..
59:586-588.
2012
-
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program..
59:518-524.
2012
-
Feasibility of neurobehavioral screening following diagnosis of pediatric cancer..
59:295-300.
2012
-
Health-related quality of life in sickle cell disease: past, present, and future..
59:377-385.
2012
-
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children..
59:365-371.
2012
-
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program..
59:329-332.
2012
-
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program..
59:246-253.
2012
-
Evaluation of partial and total splenectomy in children with sickle cell disease using an Internet-based registry..
59:100-104.
2012
-
Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort..
59:126-132.
2012
-
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program..
59:185-188.
2012
-
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program..
58:916-923.
2012
-
Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program..
58:729-735.
2012
-
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling..
58:815-818.
2012
-
A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children..
58:513-518.
2012
-
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program..
58:566-571.
2012
-
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program..
58:636-639.
2012
-
Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program..
58:191-199.
2012
-
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program..
58:200-209.
2012
-
Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia..
58:31-36.
2012
-
Childhood cancer survivorship educational resources in North American pediatric hematology/oncology fellowship training programs: a survey study..
57:1186-1190.
2011
-
Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice..
57:1239-1243.
2011
-
Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study..
57:1210-1216.
2011
-
Initial testing of lenalidomide by the pediatric preclinical testing program..
57:606-611.
2011
-
Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program..
57:443-453.
2011
-
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program..
57:268-274.
2011
-
ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy..
56:1055-1061.
2011
-
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group..
56:1041-1045.
2011
-
Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan..
56:818-824.
2011
-
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program..
56:595-603.
2011
-
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program..
55:1329-1337.
2010
-
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program..
55:1126-1133.
2010
-
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program..
55:668-677.
2010
-
Spontaneous resolution of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis..
55:754-756.
2010
-
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program..
55:295-303.
2010
-
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)..
55:26-34.
2010
-
Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program..
54:921-926.
2010
-
Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group..
54:663-669.
2010
-
Initial testing of topotecan by the pediatric preclinical testing program..
54:707-715.
2010
-
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group..
54:596-602.
2010
-
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia..
54:199-205.
2010
-
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program..
54:307-310.
2010
-
Health related quality of life in sickle cell disease: just scratching the surface..
54:1-2.
2010
-
Survivors of childhood cancer: an Australian audit of vaccination status after treatment..
54:128-133.
2010
-
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program..
53:1255-1263.
2009
-
Survey of long-term follow-up programs in the United States for survivors of childhood brain tumors..
53:1295-1301.
2009
-
Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection..
53:1120-1123.
2009
-
Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program..
53:594-598.
2009
-
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program..
53:505-508.
2009
-
Initial testing of aplidin by the pediatric pre-clinical testing program..
53:509-512.
2009
-
Measuring psychosocial risk in families caring for a child with cancer: the Psychosocial Assessment Tool (PAT2.0)..
53:78-83.
2009
-
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia..
52:609-615.
2009
-
Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia..
52:531-534.
2009
-
Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome..
52:536-538.
2009
-
Assessment of selection bias in clinic-based populations of childhood cancer survivors: a report from the childhood cancer survivor study..
52:379-386.
2009
-
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors..
52:169-176.
2009
-
Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma..
51:675-678.
2008
-
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program..
51:439-441.
2008
-
Abnormalities in glucose tolerance are common in children with fanconi anemia and associated with impaired insulin secretion..
51:256-260.
2008
-
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program..
51:42-48.
2008
-
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program..
51:34-41.
2008
-
A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation..
50:1240-1246.
2008
-
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program..
50:1190-1197.
2008
-
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program..
50:1181-1189.
2008
-
Initial testing of dasatinib by the pediatric preclinical testing program..
50:1198-1206.
2008
-
Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease..
50:1006-1012.
2008
-
Initial testing of cisplatin by the pediatric preclinical testing program..
50:992-1000.
2008
-
Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia..
50:1072-1075.
2008
-
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program..
50:799-805.
2008
-
Acute myelogenous leukemia associated with Ollier disease..
50:645-646.
2008
-
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program..
50:581-587.
2008
-
Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?.
50:462-467.
2008
-
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program..
50:37-45.
2008
-
Reply to Comment on "Use of Patient Registries and Administrative Datasets for the Study of Pediatric Cancer"..
63:368.
2016
-
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.
2017